Company profile: Manhattan Pharma
1.1 - Company Overview
Company description
- Provider of specialty healthcare product development and commercialization focused on innovative treatments for underserved patient populations, advancing a portfolio of product candidates.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Manhattan Pharma
Fortress Biotech
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, focused on acquiring, developing and commercializing therapeutic products. Pipeline: Cosibelimab (fully human PD-L1 antibody) for EGFR mutation–positive non-small cell lung cancer; DFD-29 for inflammatory lesions of rosacea; IV Tramadol for post-surgical pain; AJ201 for spinal and bulbar muscular atrophy; BAER-101 for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fortress Biotech company profile →
Propagenix
HQ: United States
Website
- Description: Provider of healthcare technology platforms for translational biomedical research, including EpiX technology to expand primary epithelial cells without genetic modification, CR feeder-cell culture to replicate epithelial cells, engineered bi-layered skin constructs, airway epithelium models and theranostic assays, and collaborative and sponsored research for drug discovery and toxicology screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Propagenix company profile →
InMed Pharmaceuticals
HQ: Canada
Website
- Description: Provider of cannabinoid-based pharmaceutical candidates and rare cannabinoid ingredients. Develops INM-755 (cannabinol topical for epidermolysis bullosa) and INM-088 (cannabinol-based for glaucoma). Through BayMedica, supplies bioidentical rare cannabinoids (CBC, d9-THCV, CBDV, CBTC) for B2B health and wellness. Offers IntegraSyn, combining biosynthesis and chemical synthesis to produce cannabinoids, aiming for high yield and cost efficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InMed Pharmaceuticals company profile →
Trevi Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for uremic pruritus and chronic cough, including Haduvio—an investigational oral nalbuphine ER therapy targeting the central and peripheral nervous systems for idiopathic pulmonary fibrosis (IPF)-related cough and refractory chronic cough (RCC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trevi Therapeutics company profile →
Microvascular Tissues
HQ: United States
Website
- Description: Provider of biological vascular tissues for implantation, including mVASC Microvascular Tissue, a sterile, off-the-shelf human microvascular tissue graft designed to restore blood flow and support natural healing in damaged tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microvascular Tissues company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Manhattan Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Manhattan Pharma
2.2 - Growth funds investing in similar companies to Manhattan Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Manhattan Pharma
4.2 - Public trading comparable groups for Manhattan Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →